Doximity, Inc. (NASDAQ:DOCS) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. trimmed its holdings in Doximity, Inc. (NASDAQ:DOCSFree Report) by 25.7% in the third quarter, Holdings Channel.com reports. The fund owned 16,863 shares of the company’s stock after selling 5,842 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Doximity were worth $735,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Farther Finance Advisors LLC raised its holdings in shares of Doximity by 324.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 789 shares of the company’s stock worth $34,000 after purchasing an additional 603 shares in the last quarter. LRI Investments LLC bought a new position in shares of Doximity in the first quarter valued at $27,000. Blue Trust Inc. lifted its position in shares of Doximity by 621.4% during the 2nd quarter. Blue Trust Inc. now owns 1,385 shares of the company’s stock valued at $37,000 after acquiring an additional 1,193 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Doximity by 40.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,439 shares of the company’s stock worth $63,000 after acquiring an additional 412 shares in the last quarter. Finally, Quarry LP grew its holdings in shares of Doximity by 101.2% in the 2nd quarter. Quarry LP now owns 1,616 shares of the company’s stock worth $45,000 after acquiring an additional 131,253 shares during the last quarter. Institutional investors own 87.19% of the company’s stock.

Doximity Trading Up 5.7 %

Shares of DOCS stock opened at $52.24 on Tuesday. Doximity, Inc. has a 1 year low of $22.96 and a 1 year high of $61.75. The firm’s fifty day simple moving average is $43.71 and its 200 day simple moving average is $34.45. The firm has a market capitalization of $9.75 billion, a P/E ratio of 60.05, a price-to-earnings-growth ratio of 4.09 and a beta of 1.30.

Wall Street Analysts Forecast Growth

DOCS has been the subject of a number of recent analyst reports. Needham & Company LLC upgraded Doximity from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research report on Friday, August 9th. Raymond James restated an “outperform” rating and set a $65.00 price target (up previously from $37.00) on shares of Doximity in a report on Friday, November 8th. Robert W. Baird boosted their target price on shares of Doximity from $41.00 to $45.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. Evercore ISI increased their price objective on Doximity from $34.00 to $45.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 8th. Finally, Baird R W upgraded Doximity to a “strong-buy” rating in a report on Tuesday, September 17th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $51.07.

Check Out Our Latest Report on Doximity

Doximity Company Profile

(Free Report)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Featured Stories

Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NASDAQ:DOCSFree Report).

Institutional Ownership by Quarter for Doximity (NASDAQ:DOCS)

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.